Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Argan (AGX) Cash & Equivalents (2016 - 2025)

Argan's Cash & Equivalents history spans 16 years, with the latest figure at $306.3 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 74.68% year-over-year to $306.3 million; the TTM value through Oct 2025 reached $306.3 million, up 74.68%, while the annual FY2025 figure was $145.3 million, 26.27% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $306.3 million at Argan, up from $177.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $451.4 million in Q3 2021 and bottomed at $136.1 million in Q4 2022.
  • The 5-year median for Cash & Equivalents is $196.5 million (2023), against an average of $241.0 million.
  • The largest annual shift saw Cash & Equivalents soared 119.09% in 2021 before it crashed 68.25% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $391.6 million in 2021, then plummeted by 65.25% to $136.1 million in 2022, then soared by 36.38% to $185.6 million in 2023, then dropped by 5.51% to $175.3 million in 2024, then surged by 74.68% to $306.3 million in 2025.
  • Per Business Quant, the three most recent readings for AGX's Cash & Equivalents are $306.3 million (Q4 2025), $177.8 million (Q3 2025), and $189.3 million (Q2 2025).